Core Insights - Scinai Immunotherapeutics (NASDAQ:SCNI) stock surged by 55.8% following the announcement of positive results from an early-stage study of its anti IL-17A/F VHH antibody fragment NanoAb, aimed at treating mild to moderate plaque psoriasis [2][4]. Company Developments - The company revealed successful results from an in-vivo preclinical study where NanoAb was tested on mice with human skin grafts infected with psoriasis, indicating its potential as a local treatment for the disease [4]. - Chief Science Officer Dr. Tamar Ben-Yedidia highlighted the significance of these results, stating they represent a major advancement in developing a treatment for patients with mild to moderate plaque psoriasis [5]. Market Activity - The trading volume of SCNI shares saw a substantial increase, with over 26 million shares traded, compared to the daily average of approximately 570,000 shares [6].
Why Is Scinai Immunotherapeutics (SCNI) Stock Up 56% Today?